ODT - オドネイト・セラピュ―ティクス （Odonate Therapeutics Inc.） オドネイト・セラピュ―ティクスODTのチャート
ODTの企業情報
| symbol | ODT |
|---|---|
| 会社名 | Odonate Therapeutics Inc （オドネイト・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 オオドン・セラピューティックス(Odonate Therapeutics Inc.)(旧名: Odonate Therapeutics LLC)は製薬会社である。同社は、がん患者の生活を改善し、寿命を延長するための治療薬の開発に従事する。同社は新しい化学療法剤であるテセタキセルの開発に焦点を当てる。同社は転移性乳がん（MBC）患者のフェーズⅡ試験を完了した。同社のテセタキセルは、低錠剤負荷および投薬計画で経口投与することができる。タキサンは、癌細胞が有糸分裂に入るのを防ぎ、それによってアポトーシス（細胞死）を引き起こすことによって癌細胞を破壊する。 オドネイト・セラピュ―ティクスは米国の医薬品企業。主にがん患者の生活の質向上と延命を目指す医薬品の開発に従事する。がん治療に利用されるタキサン類の薬剤に属するテセタキセルは、経口投薬が可能で、過敏症反応を引き起こす可溶化剤を含まず、化学療法に耐性を示す腫瘍に対し改善された活性を有する。本社所在地はカリフォルニア州サンディエゴ。 Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives. |
| 本社所在地 | 4747 Executive Drive Suite 510 San Diego CA 92121 USA |
| 代表者氏名 | Kevin C. Tang ケヴィン・C・タング |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 858-200-3830 |
| 設立年月日 | 41334 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2017年 |
| 従業員数 | － |
| url | www.odonate.com |
| nasdaq_url | https://www.nasdaq.com/symbol/odt |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -62.70300 |
| 終値（lastsale） | 16.59 |
| 時価総額（marketcap） | 446133153.69 |
| 時価総額 | 時価総額（百万ドル） 410.63610 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 233.20910 |
| 当期純利益 | 当期純利益（百万ドル） -62.38900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Odonate Therapeutics Inc revenues was not reported. Net loss increased from $6.6M to $36.3M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.25 to -$1.49. |
ODTのテクニカル分析
ODTのニュース
Odonate Therapeutics Inc Shares Close the Day 16.8% Lower - Daily Wrap 2022/01/09 04:35:42 Kwhen Finance
Odonate Therapeutics Inc (ODT) shares closed today 16.8% lower than it did at the end of yesterday. The stock is currently down 19.3% year-to-date, down 94.5% over the past 12 months, and down 95.3% over the past five years. Today, the Dow Jones Industrial Average fell 0.0%, and the S&P 500 fell 0.4%. Trading Activity Shares traded as high as $1.56 and as low as $0.85 this week.Shares closed 96.2% below its 52-week high and 28.2% above its 52-week low.Trading volume this week was 89.0% lower than the 10-day average and 86.2% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -1296.8% The company's stock price performance over the past 12 months lags the peer average by 14859.9%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Odonate Therapeutics Inc Shares Near 52-Week Low - Market Mover 2022/01/07 12:10:07 Kwhen Finance
Odonate Therapeutics Inc (ODT) shares closed today at 0.8% above its 52 week low of $1.30, giving the company a market cap of $50M. The stock is currently down 3.0% year-to-date, down 93.1% over the past 12 months, and down 94.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 61.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -655.2% The company's stock price performance over the past 12 months lags the peer average by 5661.3%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
SHAREHOLDER ALERT: Morris Kandinov Investigating CORT, MTCH, LDI, and ODT; Shareholders are Encouraged to Contact the Firm 2021/12/22 21:53:00 Intrado Digital Media
SAN DIEGO, Dec. 22, 2021 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Corcept Therapeutics, Inc., Match Group, Inc., Inc., loanDepot, Inc., and Odonate Therapeutics, Inc. If you are a current owner of shares of any of these stocks, contact leo@moka.law or call (619) 780-3993.
Odonate Therapeutics, Inc. (NASDAQ:ODT) Sees Large Increase in Short Interest 2021/12/17 17:20:41 Dakota Financial News
Odonate Therapeutics, Inc. (NASDAQ:ODT) was the target of a large growth in short interest in November. As of November 30th, there was short interest totalling 513,400 shares, a growth of 85.0% from the November 15th total of 277,500 shares. Based on an average trading volume of 604,900 shares, the short-interest ratio is currently 0.8 days. []
Insider Buying: Odonate Therapeutics, Inc. (NASDAQ:ODT) Major Shareholder Acquires $308,662.06 in Stock 2021/12/13 10:14:41 Dakota Financial News
Odonate Therapeutics, Inc. (NASDAQ:ODT) major shareholder Ecor1 Capital, Llc purchased 185,941 shares of the companys stock in a transaction dated Wednesday, December 1st. The stock was purchased at an average price of $1.66 per share, for a total transaction of $308,662.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, []